2016
Comparison of Intensive Case Management for Psychotic and Nonpsychotic Patients
Mohamed S. Comparison of Intensive Case Management for Psychotic and Nonpsychotic Patients. Psychological Services 2016, 13: 10-19. PMID: 26168139, DOI: 10.1037/ser0000041.Peer-Reviewed Original ResearchConceptsAssertive community treatmentPsychotic symptomsAnalysis of covariancePsychotic disordersIntensive case management programIntensive case management servicesSevere psychotic symptomsIntensive case managementCommunity-based careCase management programCase management servicesInpatient bed availabilityCommunity-based service programsBaseline characteristicsMedication complianceNonpsychotic patientsNonpsychotic disordersOutcome dataPsychotic diagnosesHospital useCommunity treatmentSuch symptomsBed availabilitySymptomsCase management
2015
Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia
Mohamed S, Rosenheck RA, Lin H, Swartz M, McEvoy J, Stroup S. Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia. The Journal Of Nervous And Mental Disease 2015, 203: 486-492. PMID: 26075840, DOI: 10.1097/nmd.0000000000000317.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAlcoholismAntipsychotic AgentsBenzodiazepinesChronic DiseaseComorbidityCross-Sectional StudiesDibenzothiazepinesDouble-Blind MethodFemaleHumansIllicit DrugsMaleMiddle AgedOlanzapinePerphenazinePiperazinesPsychiatric Status Rating ScalesQuetiapine FumarateRisperidoneSchizophreniaSchizophrenic PsychologySmokingSmoking PreventionSubstance-Related DisordersThiazolesYoung AdultConceptsSecond-generation antipsychotic drugsAntipsychotic drugsFirst-generation antipsychoticsSecond-generation antipsychoticsIntervention Effectiveness (CATIE) studySecondary outcome dataClinical Antipsychotic TrialsFirst-generation drugsSubstance use outcomesCigarette smokingSchizophrenia trialsChronic schizophreniaAntipsychotic TrialsOutcome dataNicotine useDrug useSecondary analysisPast weekAntipsychoticsEffectiveness studiesPatientsSubstance useUse outcomesTrialsDrugs
1999
Will the novel antipsychotics significantly ameliorate neuropsychological deficits and improve adaptive functioning in schizophrenia?
HAWKINS KA, MOHAMED S, WOODS SW. Will the novel antipsychotics significantly ameliorate neuropsychological deficits and improve adaptive functioning in schizophrenia? Psychological Medicine 1999, 29: 1-8. PMID: 10077288, DOI: 10.1017/s0033291798006990.Peer-Reviewed Original ResearchConceptsNovel antipsychoticsNegative symptomsNeuropsychological deficitsSevere psychiatric illnessNew antipsychotic medicationsTreatment of schizophreniaCognitive outcome dataAntipsychotic medicationConventional neurolepticsNeurodevelopmental aberrationsClinical effectivenessNew antipsychoticsUnderlying pathophysiologyClinical reasonsPsychiatric illnessImproved complianceOutcome dataFunctional capacityNeurological effectsAntipsychoticsAuditory hallucinationsNeurocognitive changesMedicationsNeural tissueSymptoms